Related Experiment Videos
Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma
L M Vargas Roig1, H Lotfi, J E Olcese
1Laboratorio de Reproducción y Lactancia, LARLAC, Mendoza, Argentina.
Abstract:
Cervical cancer is not considered a hormone-responsive tumor in spite of the presence of estrogen receptors (ER) and progesterone receptors (PgR) in some of them. Endocrine treatments have not achieved clinical responses, however, tamoxifen has been reported to induce PgR and to inhibit cell growth of many cervical carcinoma cell lines. In this study we investigated whether tamoxifen administration affects the histopathological characteristics of cervical cancer and the expression of ER, PgR, HER-2/neu and p53 protein. Nineteen patients with invasive cervical cancer free of previous treatments were studied. The triphenylethylene antiestrogen tamoxifen was given orally during 10 days (20 or 40 mg/day). Pre- and post-tamoxifen biopsies were evaluated using slides stained with hematoxylin and eosin and immunostained (ER, PgR, HER-2/neu, p53, PCNA, keratin, heat shock protein 27,000 daltons). Estrogen receptors were present in 37% and PgR in 16% of the biopsies from untreated patients. Only one case that was PgR-negative before tamoxifen administration showed weak PgR-positivity following antiestrogen administration. No obvious changes were observed in ER, HER-2/neu and p53 proteins. A statistically significant decrease in the number of mitotic figures was obtained in 16% (3/19) of the post-tamoxifen biopsies and two of them showed higher differentiation. The results showed that tamoxifen did not induce changes in estrogen-regulated proteins in cervical cancer. However, the data showed that certain cervical carcinomas had changes in their proliferation and differentiation levels following tamoxifen administration. These findings suggest that tamoxifen may affect some cervical cancer tissues by a hormone-independent mechanism(s).
Insights
Tamoxifen did not alter estrogen or progesterone receptors in cervical cancer patients. However, it did reduce cell proliferation and increase differentiation in some cases, suggesting a hormone-independent effect.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Pharmacology
Background:
- Cervical cancer is not typically considered hormone-responsive, despite some tumors expressing estrogen receptors (ER) and progesterone receptors (PgR).
- Endocrine therapies have shown limited clinical efficacy in cervical cancer.
- Tamoxifen, an antiestrogen, has demonstrated potential to inhibit cervical carcinoma cell growth in vitro.
Purpose of the Study:
- To investigate the effects of tamoxifen on histopathological characteristics and protein expression (ER, PgR, HER-2/neu, p53) in invasive cervical cancer.
- To determine if tamoxifen influences estrogen-regulated pathways in cervical cancer tissues.
Main Methods:
- Nineteen treatment-naive patients with invasive cervical cancer received oral tamoxifen (20 or 40 mg/day) for 10 days.
- Pre- and post-treatment biopsies were analyzed using hematoxylin and eosin staining and immunohistochemistry for ER, PgR, HER-2/neu, p53, PCNA, keratin, and heat shock protein.
- Changes in protein expression, mitotic figures, and differentiation were evaluated.
Main Results:
- Estrogen receptors (ER) were present in 37% and progesterone receptors (PgR) in 16% of untreated biopsies.
- Tamoxifen administration did not significantly alter ER, HER-2/neu, or p53 protein expression.
- A statistically significant decrease in mitotic figures was observed in 16% of post-tamoxifen biopsies, with two cases showing increased differentiation.
Conclusions:
- Tamoxifen does not appear to induce significant changes in estrogen-regulated proteins in cervical cancer.
- The observed alterations in proliferation and differentiation suggest tamoxifen may exert effects through hormone-independent mechanisms in some cervical carcinomas.
- Further research is warranted to elucidate the non-hormonal pathways through which tamoxifen might impact cervical cancer tissues.